Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024
The New York City-based company is expected to report revenue of $85.912 million, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $35.50, above its last closing price of $15.28.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.14 | -1.11 | -0.98 | Beat | 11.9 |
Jun. 30 2024 | -0.91 | -0.91 | -0.80 | Beat | 12.5 |
Mar. 31 2024 | -0.96 | -0.98 | -0.85 | Beat | 13.1 |
Dec. 31 2023 | -0.97 | -0.99 | -1.00 | Missed | -0.6 |
Sep. 30 2023 | -0.80 | -0.80 | -0.73 | Beat | 8.2 |
Jun. 30 2023 | -0.73 | -0.73 | -0.64 | Beat | 12.6 |
Mar. 31 2023 | -0.60 | -0.60 | -0.59 | Beat | 1 |
Dec. 31 2022 | -0.65 | -0.65 | -0.62 | Beat | 4.4 |
This summary was machine generated February 28 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。